english Icono del idioma   español Icono del idioma  

Por favor, use este identificador para citar o enlazar este ítem: https://hdl.handle.net/20.500.12008/54656 Cómo citar
Registro completo de metadatos
Campo DC Valor Lengua/Idioma
dc.contributor.authorGulayin, Pablo E.-
dc.contributor.authorLozada, Alfredo-
dc.contributor.authorSchreier, Laura-
dc.contributor.authorIrazola, Vilma-
dc.contributor.authorGutiérrez, Laura-
dc.contributor.authorLópez, G. I.-
dc.contributor.authorPoggio, Rosana-
dc.contributor.authorMores, Nora-
dc.contributor.authorPonzo, Jacqueline-
dc.contributor.authorCalandrelli, Matías-
dc.contributor.authorLanas, Fernando-
dc.date.accessioned2026-04-28T19:30:46Z-
dc.date.available2026-04-28T19:30:46Z-
dc.date.issued2022-
dc.identifier.citationGulayin P, Lozada A, Schreier L y otros. Elevated Lipoprotein(a) prevalence and association with family history of premature cardiovascular disease in general population with moderate cardiovascular risk and increased LDL cholesterol. IJC Heart and Vasculature [en línea]. 2022;42. 5 p.es
dc.identifier.urihttps://hdl.handle.net/20.500.12008/54656-
dc.description.abstractBackground: Elevated Lipoprotein(a) [Lp(a)] is independently associated with increased cardiovascular disease (CVD) risk. There are discrepancies regarding its epidemiology due to great variability in different populations. This study aimed to evaluate the prevalence of elevated Lp(a) in people with moderate CVD risk and increased LDL-c and to determine the association between family history of premature CVD and elevated Lp(a). Methods: Random subjects from the CESCAS population-based study of people with moderate CVD risk (Framingham score 10–20 %) and LDL-c ≥ 130 mg/dL, were selected to evaluate Lp(a) by immunoturbidimetry independent of the Isoforms variability. The association between family history of premature CVD and elevated Lp(a) was evaluated using multivariate logistic regression models. Elevated Lp(a) was defined as Lp(a) ≥ 125 nmol/L. Results: Lp(a) was evaluated in 484 samples; men = 39.5 %, median age = 57 years (Q1-Q3: 50–63), mean CVD risk = 14.4 % (SE: 0.2), family history of premature CVD = 11.2 %, Lp(a) median of 21 nmol/L (Q1-Q3: 9–42 nmol/L), high Lp(a) = 6.1 % (95 % CI = 3.8–9.6). Association between family history of premature CVD and elevated Lp(a) in total population: OR 1.31 (95 % CI = 0.4, 4.2) p = 0.642; in subgroup of people with LDL-c ≥ 160 mg%, OR 4.24 (95 % CI = 1.2, 15.1) p = 0.026. Conclusions: In general population with moderate CVD risk and elevated LDL-c from the Southern Cone of Latin America, less than one over ten people had elevated Lp(a). Family history of premature CVD was significantly associated with the presence of elevated Lp(a) in people with LDL-c ≥ 160 mg/dL.es
dc.format.extent5 p.es
dc.format.mimetypeapplication/pdfes
dc.language.isoenes
dc.publisherElsevieres
dc.relation.ispartofIJC Heart and Vasculature. 2022;42es
dc.rightsLas obras depositadas en el Repositorio se rigen por la Ordenanza de los Derechos de la Propiedad Intelectual de la Universidad de la República.(Res. Nº 91 de C.D.C. de 8/III/1994 – D.O. 7/IV/1994) y por la Ordenanza del Repositorio Abierto de la Universidad de la República (Res. Nº 16 de C.D.C. de 07/10/2014)es
dc.subjectLipoprotein(a)es
dc.subjectCVD family historyes
dc.subjectLDL cholesteroles
dc.subjectCardiovascular disease riskes
dc.subject.otherANAMNESISes
dc.subject.otherLIPOPROTEÍNA(A)es
dc.subject.otherENFERMEDADES CARDIOVASCULARESes
dc.subject.otherFACTORES DE RIESGO DE ENFERMEDAD CARDIACAes
dc.subject.otherLDL-COLESTEROLes
dc.subject.otherEPIDEMIOLOGÍAes
dc.subject.otherPREVALENCIAes
dc.titleElevated Lipoprotein(a) prevalence and association with family history of premature cardiovascular disease in general population with moderate cardiovascular risk and increased LDL cholesteroles
dc.typeArtículoes
dc.contributor.filiacionGulayin Pablo E., Universidad Nacional de La Plata (Argentina). Facultad de Ciencias Médicas-
dc.contributor.filiacionLozada Alfredo, Universidad Austral (Argentina). Centro de Lípidos-
dc.contributor.filiacionSchreier Laura, Universidad de Buenos Aires (Argentina). Facultad de Farmacia y Bioquímica-
dc.contributor.filiacionIrazola Vilma, Instituto de Efectividad Clínica y Sanitaria (Argentina)-
dc.contributor.filiacionGutiérrez Laura, Instituto de Efectividad Clínica y Sanitaria (Argentina)-
dc.contributor.filiacionLópez G. I., Universidad de Buenos Aires (Argentina). Facultad de Farmacia y Bioquímica-
dc.contributor.filiacionPoggio Rosana, Instituto de Efectividad Clínica y Sanitaria (Argentina)-
dc.contributor.filiacionMores Nora, Municipalidad de Marcos Paz (Argentina)-
dc.contributor.filiacionPonzo Jacqueline, Universidad de la República (Uruguay). Facultad de Medicina-
dc.contributor.filiacionCalandrelli Matías, Sanatorio San Carlos (Argentina)-
dc.contributor.filiacionLanas Fernando, Universidad de La Frontera (Chile)-
dc.rights.licenceLicencia Creative Commons Atribución - No Comercial - Sin Derivadas (CC - By-NC-ND 4.0)es
dc.identifier.doi10.1016/j.ijcha.2022.101100-
dc.identifier.eissn2352-9067-
Aparece en las colecciones: Publicaciones Académicas y Científicas - Facultad de Medicina

Ficheros en este ítem:
Fichero Descripción Tamaño Formato   
Elevated Lipoprotein prevalence.pdf Elevated Lipoprotein prevalence5,57 MBAdobe PDFVisualizar/Abrir


Este ítem está sujeto a una licencia Creative Commons Licencia Creative Commons Creative Commons